Media stories about Aduro BioTech (NASDAQ:ADRO) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aduro BioTech earned a news sentiment score of 0.06 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.3534203741478 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Several brokerages have recently weighed in on ADRO. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Aduro BioTech in a research report on Wednesday, September 27th. Oppenheimer set a $15.00 price objective on Aduro BioTech and gave the stock a “buy” rating in a report on Monday, December 11th. Canaccord Genuity set a $30.00 price objective on Aduro BioTech and gave the stock a “buy” rating in a report on Thursday, December 14th. William Blair reissued an “outperform” rating on shares of Aduro BioTech in a research note on Monday, October 2nd. Finally, BidaskClub lowered Aduro BioTech from a “hold” rating to a “sell” rating in a research note on Saturday, December 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $17.71.
Aduro BioTech (NASDAQ ADRO) traded up $0.10 during midday trading on Friday, hitting $6.90. The stock had a trading volume of 349,800 shares, compared to its average volume of 400,500. Aduro BioTech has a 12-month low of $6.01 and a 12-month high of $14.05. The company has a market cap of $525.66, a PE ratio of -5.07 and a beta of 3.52.
Aduro BioTech (NASDAQ:ADRO) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.03). The company had revenue of $3.79 million during the quarter, compared to the consensus estimate of $4.04 million. Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. Aduro BioTech’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.54) earnings per share. research analysts anticipate that Aduro BioTech will post -1.28 earnings per share for the current fiscal year.
In related news, CEO Stephen T. Isaacs sold 16,400 shares of Aduro BioTech stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $7.96, for a total value of $130,544.00. Following the completion of the transaction, the chief executive officer now owns 190,321 shares in the company, valued at $1,514,955.16. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Dirk G. Brockstedt sold 65,223 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $8.11, for a total value of $528,958.53. Following the transaction, the executive vice president now owns 137,826 shares of the company’s stock, valued at approximately $1,117,768.86. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 267,714 shares of company stock valued at $2,251,452. Company insiders own 6.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://ledgergazette.com/2018/01/19/aduro-biotech-adro-receiving-somewhat-favorable-media-coverage-analysis-finds.html.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.